Table 2.

Impact of nodal status on systemic therapy recommendations.

HER2+
T1aN0	T1bc N0	Stage II/III
Consider TH	TH chemotherapy	ACT or TC plus trastuzumab, ± pertuzumab
Triple Negative
T1a N0	T1bc N0	Stage II/III
Consider chemotherapy	TC or ACT	ACT

HR+, HER2−
Premenopausal* Node Negative	Postmenopausal Node Negative, 1-3+ nodes
Oncotype score >25   Chemotherapy + endocrine therapy	Oncotype score >25   Chemotherapy + endocrine therapy
Oncotype score ≤15   Endocrine therapy	Oncotype score ≤25   Endocrine therapy
Oncotype score 16-25   Consider chemotherapy
Node positive
Chemotherapy

^*Nodal status primary determinant of need for chemotherapy

Abbreviations: HER2, human epidermal growth factor receptor 2; TH, taxane and trastuzumab; ACT, anthracycline, cyclophosphamide, Taxane; TC, carboplatin taxane; HR, hormone receptor;